Poynovo (ASX:PNV) announced to the market that it had a record monthly sales of $A10.1m (unaudited) for November 2024.

Highlights:

• The U.S. business grew strongly, with monthly sales of $A7.0m (unaudited) and YTD November sales of $A33.9m are up $A7.3m or 27.3% on STLY.

• Rest of World had monthly sales of $A3.1m (unaudited) and YTD November sales of $A10.5m are up $A2.0m or 24.0% on STLY. After attaining market leadership in UK and Germany in full thickness burns, we continue to disrupt the market by expanding into soft-tissue reconstruction use cases in UK and Germany by displacing the current gold standard in oncological excisions and surgical dermatology.

• Total group revenue for the month, including BARDA was $A11.0m (unaudited), and YTD November group revenue of $A49.6m is up $A10.1m or 25.4% on STLY.

Particularly pleased with the growth in Rest of the World (ROW) Monthly sales.

David Williams providing milestone monthly sales results will serve well enough for interim updates.

Keen to see how NovoSorb MTX uptake continues from here.

Will continue to hold both in RL and here on SM.

3A658854_PNV.pdf

PolyNovo announced today that the first patient has been enrolled in their funded burn study. This study trial is being carried out in 20 US and 5 Canadian burn centres and will have up to 150 full thickness burn patients in a comparative study against the existing standard of care. The study is estimated to take about 3 years.
When the study concludes, Polynovo will make a premarket approval application with the US FDA for the use of their patented NovoSorb product in treating full thickness burns. 

I'm very confident that the data from this study will accelerate the use of Novosorb as the preferred standard of care when treating full thickness burns patients.